Metabolic & Cardiometabolic
dietary fiber decreases GLP-1 resistance
In plain terms: Does fibre help your body respond better to its own appetite-suppressing hormone GLP-1?
Leans support Metabolic & Cardiometabolic 🔬 Includes disconfirming
Part of: 🧪 dietary fiber
RefutedContestedStrong support
consensus score 0.30
Probably yes as a mechanism, but only shown in the lab and cells so far, not in people.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
10 support 1 contradict 2 tested null 3 mixed · 16 sources, 11 independent groups
What the evidence shows
Fiber/beta-glucan maintain tight junctions (occludin, ZO-1), lowering LPS translocation and endotoxemia, which de-represses GLP-1 signaling (GPR41/43, FXR, TGR5). Directly names a fiber already in the bakery program — a defensible 'reduce GLP-1 resistance' hypothesis, but review-grade.
The evidence (23)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Chambers ES, Morrison DJ, Frost G 2015 · Proc Nutr Soc | mechanism | supports | moderate | Narrative review, no new data; it concerns SCFA-stimulated GLP-1/PYY secretion and appetite ('The present review therefore proposes that an elevated colonic production of SCFA could stimulate numerous hormonal and neural signals ... that would cumulatively suppress short-term appetite and energy intake'), not GLP-1 resistance or barrier function. Zero weight. |
| Rukeye A, Shang T, Maierheba K, Zhao Y, Dina M, Yu W, Liu M, Han J 2026 · Wei sheng yan jiu = Journal of hygiene research | animal | supports | low | Wheat bran (10-15% dietary fiber) fed to high-fat-diet Sprague-Dawley rats for 12 weeks reduced hepatic/colonic oxidative stress (SOD, GSH-Px up; MDA down), ameliorated colonic mucosal histopathology, and increased serum/colonic GLP-1 vs hi |
| de Freitas Queiroz Barros HD, Casagrande BP, Araújo DD, Mutran TAJ, Telles MM, Estadella D, Pisani LP 2026 · Rev Endocr Metab Disord | mechanism | mixed | low | Narrative review: 'This review summarizes mechanistic and translational evidence showing that diet-induced changes in the gut microbiota contribute to altered signaling along the gut-hypothalamus-adipose tissue axis.' No fiber intervention or GLP-1 resistance measure of its own. Review — zero weight. |
| Zhang Y, Wang DD 2026 · Gut microbes | observational | supports | low | Review of T2D gut microbiome multi-omics describes reduced SCFA/secondary bile acid production and increased endotoxin-related metabolism linked to gut barrier integrity, inflammatory tone, and insulin sensitivity, but does not address GLP |
| Chambers ES, Viardot A, Psichas A, Morrison DJ, Murphy KG, Zac-Varghese SE, MacDougall K, Preston T, Tedford C, Finlayson GS, Blundell JE, Bell JD, Thomas EL, Mt-Isa S, Ashby D, Gibson GR, Kolida S, Dhillo WS, Bloom SR, Morley W, Clegg S, Frost G 2015 · Gut | RCT | supports | moderate | Colonic propionate delivery raised PYY/GLP-1 secretion and reduced energy intake/weight gain in overweight adults. |
| Christiansen CB, Gabe MBN, Svendsen B, Dragsted LO, Rosenkilde MM, Holst JJ 2018 · Am J Physiol GI | in-vitro | supports | moderate | SCFAs stimulate colonic GLP-1 secretion (ex-vivo) |
| Rahat-Rozenbloom S, Fernandes J, Cheng J, Wolever TMS 2017 · Eur J Clin Nutr | RCT | contradicts | moderate | Acute inulin-driven rises in serum SCFA did not increase GLP-1 or PYY in lean/overweight humans (possible SCFA resistance). |
| Sun LY, Sun GY, Nan Y, Wang HR, Sun Y, Shi Y, Yang YF, Wang QF 2026 · Frontiers in nutrition | mechanism | supports | low | Narrative review on diabetic kidney disease describes fiber fermentation producing SCFAs (e.g. butyrate) with anti-inflammatory/renal-protective effects, and intestinal barrier dysfunction/metabolic endotoxemia as drivers of a systemic infl |
| Meng Y, Li S, Zhou K, Suonan Z, Dai Z, Shen Q, Xue Y 2026 · Food chemistry | animal | supports | low | Oat β-glucan given to obese mice improved glucose tolerance/insulin resistance and increased GLP-1 secretion via gut-microbiota-driven secondary bile acid (FXR inhibition) and succinate-mediated intestinal gluconeogenesis pathways. |
| Hirdaramani A, Cheng CW, Hanyaloglu AC, Frost G 2026 · Communications Biology | in-vitro | mixed | low | Butyrate via FFAR2-Gai programs human L-cell identity and a PYY-biased secretory profile; amplifiable pharmacologically. |
| Mazhar M, Zhu Y, Qin L 2023 · Foods | observational | supports | low | Review: dietary-fiber-derived SCFAs enhance GLP-1/PYY release via GPR41/43 and improve insulin sensitivity in T2D. |
| Yang W, Hao C, Wang N, Xie J, Zhou B, Yang Z, Zheng A, Wei J, Li C, Xie C, Li H, Lei G, Zeng C 2026 · Gut Microbes | mechanism | mixed | low | Narrative review: 'This review outlines the mechanisms through which the GM regulates GLP-1 secretion.' Fiber enters only as SCFA substrate; no GLP-1 resistance measure. Review — zero weight. |
| Nilsson AC, Ostman EM, Holst JJ, Björck IM 2008 · J Nutr | RCT | supports | moderate | Indigestible carbohydrate at evening meal improved next-morning glucose tolerance with higher GLP-1 and colonic fermentation. |
| Hamdan A, Al Nabhani Z 2026 · Current opinion in clinical nutrition and metabolic care | mechanism | supports | low | Narrative review states diet-induced dysbiosis alters intestinal barrier integrity, promotes metabolic endotoxemia, and impairs enteroendocrine hormone secretion, with fiber enrichment cited among interventions that can partially restore mi |
| Zhang L, Ouyang Y, Li H, Shen L, Ni Y, Fang Q, Wu G, Qian L, Xiao Y, Zhang J, Yin P, Panagiotou G, Xu G, Ye J, Jia W 2019 · Sci Rep | RCT | mixed | low | 40g/d RS2 crossover increased acetate, early-phase insulin/C-peptide/GLP-1 and reduced visceral fat in normal-weight subjects. |
| van der Beek CM, Canfora EE, Kip AM, Gorissen SHM, Olde Damink SWM, van Eijk HM, Holst JJ, Blaak EE, Dejong CHC, Lenaerts K 2018 · Metabolism | RCT | mixed | moderate | Acute single-dose crossover (n=14): 'There were no effects on plasma triglycerides, free glycerol, satiety hormones GLP-1 and PYY' - a hormone-level null, not a measure of GLP-1 resistance or barrier function. Off-scope. |
| Ganguly NK, Kalra S, Kapoor N, Rao P, Bakshi M 2026 · Advances in therapy | mechanism | supports | low | Commentary on India's 'thin-fat phenotype' describes impaired dietary fiber fermentation, reduced SCFA, metabolic endotoxemia and SCFA-mediated incretin secretion as interconnected drivers of metabolic vulnerability, citing emerging RCTs of |
| Irfan Z, Halder J, Giri S, Molla EA, Khanam S 2026 · Diabetes Res Clin Pract | meta-analysis | mixed | moderate | Prebiotics raise SCFA-FFAR2/3-driven GLP secretion; human incretin effects modest/variable by fiber type, dose, baseline microbiota. |
| Deng H, Zhang R 2026 · Metabolites | observational | mixed | low | Review of TCM-derived compounds in MASLD describes polysaccharides/other natural compounds repairing intestinal mucosal barrier and regulating SCFA/bile-acid metabolism via FXR/TGR5/TLR4 pathways relevant to metabolic disease, but focuses o |
| Kaji I, Karaki S, Kuwahara A 2014 · Digestion | mechanism | supports | moderate | Review of SCFA receptor (FFAR2/GPR43) contribution to GLP-1 release from enteroendocrine L-cells. |
| Hunt JE, Christiansen CB, Yassin M, Hartmann B, Offermanns S, Dragsted LO, Holst JJ, Kissow H 2024 · Metabolites | animal | tested-null | moderate | SCFAs induce GLP-1 via FFAR2/3 in perfused colon, but fiber-free-diet colitis severity was independent of the SCFA-FFAR2/3-GLP-1 pathway. |
| Ali M, Shen L, Lou S, Zhang Y 2026 · Int J Biol Macromol | mechanism | supports | low | Bioactive polysaccharides (beta-glucan) -> tight-junction maintenance -> lower LPS -> support GLP-1 |
| Maziarz MP, Preisendanz S, Juma S, Imrhan V, Prasad C, Vijayagopal P 2017 · Nutrition Journal | RCT | tested-null | low | HAM-RS2 improved postprandial glucose but did not significantly raise GLP-1/PYY or reduce adiposity in overweight adults. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.